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Abstract
Background: Mammographic population screening in The Netherlands has increased the number of breast cancer
patients with small and non-palpable breast tumors. Nevertheless, mammography is not ultimately sensitive and
specific for distinct subtypes. Molecular imaging with targeted tracers might increase specificity and sensitivity of
detection. Because development of new tracers is labor-intensive and costly, we searched for the smallest panel of
tumor membrane markers that would allow detection of the wide spectrum of invasive breast cancers.
Methods: Tissue microarrays containing 483 invasive breast cancers were stained by immunohistochemistry for a
selected set of membrane proteins known to be expressed in breast cancer.
Results: The combination of highly tumor-specific markers glucose transporter 1 (GLUT1), epidermal growth factor
receptor (EGFR), insulin-like growth factor-1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2),
hepatocyte growth factor receptor (MET), and carbonic anhydrase 9 (CAIX) 'detected' 45.5% of tumors, especially
basal/triple negative and HER2-driven ductal cancers. Addition of markers with a 2-fold tumor-to-normal ratio
increased the detection rate to 98%. Including only markers with >3 fold tumor-to-normal ratio (CD44v6) resulted
in an 80% detection rate. The detection rate of the panel containing both tumor-specific and less tumor-specific
markers was not dependent on age, tumor grade, tumor size, or lymph node status.
Conclusions: In search of the minimal panel of targeted probes needed for the highest possible detection rate, we
showed that 80% of all breast cancers express at least one of a panel of membrane markers (CD44v6, GLUT1, EGFR,
HER2, and IGF1-R) that may therefore be suitable for molecular imaging strategies. This study thereby serves as a
starting point for further development of a set of antibody-based optical tracers with a high breast cancer
detection rate.
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Background
In The Netherlands, the lifetime risk to develop breast
cancer increased in the last decades from 1 in 10 in
1989 to 1 in 7 in 2003 [1]. In parallel, the annual num-
ber of newly diagnosed cases of breast cancer rose to
over 13,000 in 2008 [2]. This makes breast cancer the
most commonly diagnosed female cancer in The Nether-
lands. Despite this increase in incidence, the number of
deaths due to breast cancer has remained stable in the
last decades, with annually around 3,300 deaths in The
Netherlands in the period 1989–2008 [3]. Early detec-
tion by mammographic population screening has likely
contributed to this, leading to diagnosis of smaller, often
non-palpable breast cancers and ductal carcinoma in
situ (DCIS) lesions [4,5]. Nevertheless, mammography is
not optimally sensitive and specific, especially in younger
patients and patients with dense breasts [6-11]. Ultra-
sonography and magnetic resonance imaging (MRI) have
been shown to contribute to early detection of breast
cancer, as has positron emission tomography (PET) im-
aging, but these three imaging devices also have their
limitations [12].
Molecular optical imaging with near-infrared fluores-
cent (NIRF) probes holds promise here [13]. First, the
spectral properties (emission wavelengths between 700–
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900 nm) of the fluorescent tracers result in low
background (auto)fluorescence [14]. Second, the detec-
tion can be highly sensitive and specific and third, it
enables to detect tumors up to centimeters deep in tis-
sue [15]. Fourth, no protective measures are required
since no ionizing radiation is emitted [16], and fifth,
NIRF probes can be conjugated to highly specific tar-
geted molecules such as antibodies, antibody fragments,
peptides, or protease activatable substrates to increase
the specificity of the signal in the tumor as reviewed by
Pleijhuis et al. [17].
Several molecular targets have been suggested to be
suitable for optical detection of breast cancer such as
the epidermal growth factor receptor (EGFR) [18], vas-
cular endothelial growth factor (VEGF) [13,19], and
(human epidermal growth factor receptor 2) HER2
[20,21]. In addition, hypoxia up-regulated surface anti-
gens like glucose transporter 1 (GLUT1) and carbonic
anhydrase 9 (CAIX) that are expressed in about half of
invasive breast cancers [22] and also in DCIS [23] and
therefore might be valuable targets. Since NIRF anti-
bodies will not be easily internalized, intracellular mo-
lecular targets relevant for optical detection of breast
cancer have so far been ignored.
However, no single molecular target is expressed in all
invasive breast cancers and at the same time provides
adequate signal-to-noise ratio to the normal breast. For
screening purposes a panel of probes, i.e. antibodies or
antibody fragments will likely be necessary. Because de-
velopment of such antibody-based probes is labor-
intensive and costly, we set out to screen for expression
of a selected set of candidate targets on tissue microar-
rays containing 483 cases of human invasive breast can-
cer, in search of the minimum antibody panel that
would be suitable for detection of most breast cancers
in vivo by molecular imaging.
Methods
Patients
The study population was derived from the archives of
the Departments of Pathology of the University Medical
Center Utrecht, Utrecht, and the Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands.
These comprised 483 cases of invasive breast cancer
(operated between 1997 and 2007), of which 340 cases
were part of a consecutive series (operated between
2003–2007). The series was enriched with a small con-
secutive series of lobular breast cancers and a consecu-
tive series of 23 cases with a BRCA germline mutation
as previously described [24].
Histological grade was assessed according to the Not-
tingham scheme [25], and mitotic activity index (MAI)
was assessed as before [26]. From representative donor
paraffin blocks of the primary tumors, tissue microarrays
were constructed by transferring tissue cylinders of
0.6 mm (3 cylinders per tumor) from the tumor area,
determined by a pathologist based on haematoxylin-
eosin stained slides, using a tissue arrayer (Beecher
Instruments, Sun Prairie, WI, USA) as described before
[27]. Normal breast tissue was obtained from patients
that underwent mammoplasty (and thus had no tumor
at all). In case of matched tumor and normal tissue, we
analyzed normal tissue in paraffin blocks that did not
contain any tumor and thus were far away from the
tumor. The use of anonymous or coded left over mater-
ial for scientific purposes is part of the standard treat-
ment contract with patients in The Netherlands [28].
Ethical approval was not required.
Immunohistochemistry
Immunohistochemistry was carried out on 4 μm thick
sections for a panel of potential molecular membrane
bound targets known to be expressed in a frequency of
>10% in breast cancer. These were partly highly tumor
specific, meaning that they have no or low intensity
staining of the normal breast tissue (GLUT1, EGFR,
insulin-like growth factor-1 receptor (IGF-1R), HER2,
CAIX, hepatocyte growth factor receptor (MET)). We
also included less tumor-specific, meaning that are
known to have moderate or high intensity staining of
the normal breast tissue (Mucin 1 (MUC1), CD44v6,
Mammaglobin, transferrin receptor (TfR), carbonic
anhydrase 12 (CAXII)), since cancers have usually
increased cellularity compared to the normal breast and
could thereby also provide adequate signal-to-noise in
tumors compared to the normal breast.
After deparaffination and rehydration, endogenous per-
oxidase activity was blocked for 15 min in a buffer solu-
tion pH5.8 containing 0.3% hydrogen peroxide. After
antigen retrieval, i.e. boiling for 20 min in 10 mM citrate
pH6.0 (for progesterone receptor (PR), CD44v6, GLUT1,
CAIX, MET, TfR, and CAXII), Tris/EDTA pH9.0 (estro-
gen receptor α (ERα), HER2, IGF1-R, MUC1, and Mam-
maglobin) or Prot K (0.15 mg/ml) for 5 min at room
temperature (EGFR), a cooling off period of 30 min pre-
ceded the primary antibody incubation. CD44v6 (clone
VFF18, BMS125 Bender MedSystems, Austria) 1:500; ERα
(clone ID5, DAKO, Glostrup Denmark) 1:200; PR (clone
PgR636, DAKO) 1:100; HER2 (SP3, Neomarkers, Duiven,
The Netherlands) 1:100; GLUT1 (A3536, DAKO) 1:200;
CAIX (ab15086, Abcam, Cambridge, UK) 1:1,000; IGF1-R
(NB110-87052, Novus Biologicals, Cambridge, UK) 1:400;
TfR (13–6800, Invitrogen, Breda, The Netherlands) 1:300;
MUC1 (EMA, M1613 clone E29, DAKO) 1:400; Ma-
mmaglobin (clone 304-1A5, DAKO) 1:100; CAXII
(HPA008773, Sigma Aldrich, Zwijndrecht, The Nether-
lands) 1:200 were incubated for 1 h at room temperature.
Primary antibodies against EGFR (clone 31 G7, Zymed,
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Invitrogen) 1:30; MET (18–2257, Zymed, Invitrogen)
1:100 were incubated overnight at 4°C. All primary anti-
bodies were diluted in PBS containing 1% BSA.
The signal was amplified using Powervision poly-HRP
anti-mouse, rabbit, rat (DPVO-HRP, Immunologic, Duiven,
The Netherlands) or the Novolink kit (Leica, Rijswijk, The
Netherlands) (in the case of EGFR) and developed with dia-
minobenzidine, followed by counterstaining with haema-
toxylin, dehydration in alcohol and mounting.
Scoring of immunohistochemistry
All stainings were compared to normal breast tissue and
scored as positive when a clear membranous staining
was seen and when the expression in the tumor was
clearly higher than in the normal breast tissue. All stain-
ings were scored using the DAKO/HER2 scoring system
for membranous staining. Scores 2+ and 3+ were con-
sidered as positive except for HER2 where only a score
of 3+ was considered positive. Due to the strong intra-
tumor heterogeneity of Mammaglobin expression, scor-
ing was performed by estimating the percentage of posi-
tive tumor cells, considering cancers with more than
35% of the membrane stained tumor cells as positive. All
scoring was done by a single experienced pathologist
(PJvD) who was blinded to patient characteristics and
results of other stainings. To take tumor-heterogeneity
between the tumor cores into account, the average score
per tumor was calculated and used for analyses. Only in
case of GLUT1 and CAIX, the tumor was classified as
positive when a single core showed positivity. In this
study a maximum of 3 missing stainings per patient was
allowed, these stainings were considered as negative in
the analyses. This potentially results in underestimation
of the percentage positivity of a marker.
Based on ERα, PR, and HER2 immunohistochemistry,
tumors were classified as luminal (ERα and/or PR posi-
tive), HER2-driven (ERα-, PR-, HER2+), triple negative
(ERα-, PR-, HER2-) or basal (ERα-, PR-, HER2-, EGFR+),
the immunohistochemical surrogate [29] of the original
Sorlie/Perou classification [30].
Immunofluorescence for quantification of protein
expression in tumor and normal breast tissue
Several of the evaluated molecular membrane targets
(CD44v6, MUC1, TfR, Mammaglobin, and CAXII) are
known to be expressed to some extent in the normal
breast epithelium. In order for these targets to be useful
for breast cancer screening by optical imaging, the signal
to background ratio needs to be high enough to be dis-
criminative. We therefore performed immunofluores-
cence with these antibodies to allow quantification of
expression ratios between normal breast and cancer tis-
sue of four randomly selected patients by image analysis.
Immunofluorescence was performed as described above
for immunohistochemistry, except that the primary anti-
bodies were detected by incubation with Goat-anti-mouse
/rabbit Alexa555 (1:1,000, Invitrogen) for 1 h at room
temperature, followed by 4,6-Diamidine-2-phenylindole
dihydrochloride (DAPI) counterstaining and mounting
with Immumount (Thermo Scientific, Etten-Leur, The
Netherlands).
Representative images of normal breast and breast can-
cers from the same sections were taken using identical set-
tings at 20x magnification using a Leica DMI4000b
inverted bright-field/fluorescence microscope.
Image analysis of tumor expression versus normal breast
tissue
Conventional immunohistochemical slides were digita-
lized for image analysis using a digital slide scanner
(Aperio Technologies Inc., Vista, CA, USA). Of each pa-
tient four representative areas of normal and tumor tis-
sue were selected and the average membrane intensity
was calculated with the IHC membrane algorithm
(Aperio, v8.001). As the signal-to-noise ratio in vivo is
determined by the difference in expression between can-
cer and normal cells as well as by cellularity, the number
of cells in the selected area was obtained from the algo-
rithm. Tumor-to-normal ratio was calculated as (mem-
brane intensity*cellularity/area) of the tumor/(membrane
intensity*cellularity/area) of normal tissue.
Tumor-to-normal ratios of the fluorescently labeled
antibodies were calculated with ImageJ using the median
intensity scores. Values are expressed as the average
tumor/normal ratio ± SEM.
Based on experience in radiology with the blood-pool
agent indocyanine green in studies assuming a leaky ves-
sel model [31,32], and from studies using NIRF labeled
trastuzumab/bevacizumab in mouse models [33], a
tumor-to-normal ratio larger than 3 was considered to
be sufficient for optical imaging.
Statistics
Statistical analysis was performed using IBM SPSS Sta-
tistics version 18.0 (SPSS Inc., Chicago, IL, USA). Asso-
ciations between categorical variables were examined
using the Pearson’s Chi-square test. P-values <0.05 were
considered to be statistically significant.
Results
To investigate the most promising combination of mar-
kers suitable for imaging, we studied the expression of a
panel of membrane markers in our study population that
comprised 319 (66.0%) invasive ductal, 126 (26.1%) inva-
sive lobular, and 38 (7.9%) invasive breast cancers with
other histology. Other clinicopathological characteristics
are shown in Table 1.
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Representative pictures of immunohistochemistry for
the highly tumor-specific molecular membrane targets are
shown in Figure 1a. The most widely expressed tumor-
specific protein in our cohort was GLUT1, positive in
20.3% of the cancers, followed by EGFR (17.4%), IGF-1R
(12.8%), HER2 (10.4%), CAIX (9.5%), and MET (8.9%).
The less tumor-specific targets MUC1 (90.7%), CD44v6
(63.8%), Mammaglobin (16.8%), TfR (14.5%), and CAXII
(8.7%) were in general more frequently expressed than the
tumor-specific targets (Table 2). Representative pictures of
immunohistochemistry for the less tumor-specific mo-
lecular membrane targets are shown in Figure 1b.
Detection rate of combinations of highly tumor-specific
molecular targets in relation to grade, molecular and
histological type
Because the frequency of expression (further denoted
'detection rate') of individual highly tumor-specific mar-
kers did not exceed 20.3% of the cases, we examined
several combinations of markers by sequential addition
of markers to the expression of GLUT1, the most widely
expressed highly tumor-specific marker. GLUT1 in com-
bination with EGFR resulted in 30.0% positive cases,
GLUT1/IGF1-R in 28.8%, GLUT1/HER2 in 27.7%,
GLUT1/MET in 25.2%, and GLUT1/CAIX in 22.3%
positive cases. The panel GLUT1, EGFR, HER2, IGF1-R,
MET, and CAIX resulted in 45.5% positive cases, al-
though the contribution of CAIX and MET was minimal
(Figure 2A).
Clear differences were found between histological sub-
types of breast cancer (Table 3). Lobular carcinomas
hardly expressed any of the tumor-specific membrane
targets present in the panel compared to ductal carcin-
omas (detection rate 18.3% vs. 55.5%, p< 0.001). Within
the group of lobular carcinomas, pleomorphic lobular
carcinomas expressed more membrane targets than clas-
sical lobular carcinomas (detection rate 26.8% vs. 8.6%,
p = 0.034). Within the group of ductal carcinomas, the
basal/triple negative (TN) and HER2-driven ductal can-
cers expressed more frequently hypoxia markers or
growth factor receptors than luminal-type ductal cancers
(detection rate 84.2% vs. 45.0%, p< 0.001) (Table 4).
Therefore the panel EGFR, MET, HER2, GLUT1, CAIX,
and IGF1-R detected 84.2% of the basal/TN ductal
breast cancers compared to 45.0% of the luminal-type,
and 18.3% of the lobular breast cancer cases (Figure 2A,
Tables 3 and 4). Because the markers included in our
panel are associated with an aggressive phenotype and
poor prognosis, we evaluated the detection rate of our
panel in relation to grade (Figure 2B). Low grade (grade
1) tumors had a detection rate of 22.5% for this panel, in
contrast to 33.7% of grade 2 and 63.9% of grade 3
tumors (p< 0.001). This indicates that the panel with
tumor-specific antigens is less sensitive for detecting
luminal-type, lobular, and low grade/well-differentiated
tumors when applied for imaging strategies.
Molecular targets that are expressed in normal breast
tissue have sufficient signal-to-noise to detect lobular and
luminal-type breast cancer
Since lobular and luminal-types of breast cancer appeared
to hardly express tumor-specific antigens, antigens that
are less tumor-specific are required for their detection.
Like with tumor-specific markers, variation between histo-
logical and molecular subtypes was observed for TfR,
Mammaglobin, and CAXII. Luminal-type ductal cancers
and lobular cancers expressed significantly more CAXII
(10.5% vs. 2.3%, p = 0.017) and Mammaglobin (19.9% vs.
5.9%, p = 0.002) compared to HER2-driven and basal/TN
ductal cancers (Tables 3 and 4). TfR expression in lobular
and luminal type ductal cancers was significantly lower
than in HER2-driven and basal/TN cancers (11.9% vs.
27.9%, p< 0.001). For MUC1 and CD44v6, no differences
in expression were found between lobular and ductal can-
cer (Tables 3 and 4).
Due to the expression of less tumor-specific antigens in
the normal breast epithelium (Figure 1B), the signal-
to-noise ratio (or tumor-to-normal) needs to be suffi-
ciently discriminating to be applicable for imaging
strategies. We determined therefore the tumor-to-normal
ratio in a quantitative manner by image analysis of digital
slides, considering a 3-fold tumor-to-normal ratio as suffi-
cient. Image quantification using conventional IHC showed
Table 1 Clinicopathological characteristics of 483 invasive
breast cancer patients studied for expression of selected
membrane markers
Feature Grouping N or value %
Age (years) Mean 60
Range 28 to 88
Histological type Invasive ductal cancer 319 66.0
Invasive lobular cancer 126 26.1
Others 38 7.9
Tumor size (cm) ≤2 206 42.7
>2 and ≤5 219 45.3
>5 49 10.1
Not available 9 1.9
Histological grade 1 89 18.4
2 169 35.0
3 219 45.4
Not available 6 1.2
Lymph node status Negative * 225 46.6
Positive ** 232 48.0
Not available 26 5.4
*: negative =N0 or N0(i+); **: positive = ≥N1mi (according to TNM 7th edition,
2010).
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that the intensity of the staining was dependent on the cel-
lularity of the tumor as expected. This resulted in tumor-
to-normal ratios of 4.8 ± 0.56, 2.3 ± 0.27, 1.2 ± 0.095,
4.6 ± 0.62, and 2.4 ± 0.88 for CD44v6, MUC1, Mammaglo-
bin, CAXII, and TfR, respectively.
Since conventional immunohistochemistry is not ne-
cessarily quantitative, we also performed immunofluor-
escence using directly fluorescently labeled antibodies.
The results were comparable with conventional immu-
nohistochemistry (Figure 3) resulting in tumor-to-
normal ratios of 3.93 ± 0.14, 2.74 ± 0.46, 1.54 ± 0.11, and
1.66 ± 0.066 for CD44v6, MUC1, Mammaglobin, and
CAXII, respectively. TfR expression was not detectable
using immunofluorescence. Thereby, CD44v6 was the
only less tumor-specific marker consistently meeting the
required 3-fold tumor-to-normal ratio.
Detection rate of combined highly and less tumor-specific
molecular targets
Including TfR, Mammaglobin, and MUC1 to the panel of
highly tumor-specific markers GLUT1, MET, EGFR,
IGF1-R, CAIX, and HER2 increased the detection rate
Figure 1 Membrane marker expression in normal breast epithelium and breast cancer. Images of representative breast cancer cases with
the corresponding normal breast epithelium that were scored as positive. A. Expression of tumor-specific markers with low or no expression in
normal breast epithelium. B. Expression of membrane markers that are also expressed in normal breast tissue. The intensity in the normal breast
epithelium was classified as moderate or high. Size bar equals 50 μm.
Vermeulen et al. BMC Cancer 2012, 12:240 Page 5 of 10
http://www.biomedcentral.com/1471-2407/12/240
from 45.5% to 49.8% (TfR), 56.4% (Mammaglobin), and
98.1% (MUC1), respectively. However, of these markers,
only CD44v6 reached a sufficiently high tumor-to-normal
ratio (see above), so adding CD44v6 to the panel of highly
specific markers therefore realistically increased the over-
all detection rate to 80.1%. When CD44v6 was included,
removal of CAIX or MET from the panel had no influence
on the detection rate.
Especially the luminal-type ductal and lobular breast
cancers were better detected by including CD44v6. Upon
addition of CD44v6, the detection rate rose from 45.5%
to 78.9% for luminal-type cancers, from 18.3% to
72.2% for the lobular breast cancers, and from 84.2% to
90.0% for basal/TN ductal breast cancers (Figure 4A).
Moreover, the detection rate of the panel was not
dependent on grade (76.4%, 74.0%, and 84.5% for grade
1, grade 2, and grade 3 tumors, respectively), tumor size
(79.1%, 77.6%, and 85.7% for tumors ≤2 cm, >2 and
≤5 cm, and >5 cm, respectively), lymph node status
(76.2% for lymph node negative, and 82.7% for lymph
node positive cases), or age (78.8% for patients <60 years
and 80.1% for patients >60 years) (Figure 4B).
Therefore, the optimal combination of membrane-
expressed proteins to target by molecular imaging
seemed to consist of CD44v6, GLUT1, EGFR, HER2,
and IGF1-R by which about 80% of invasive breast can-
cers are predicted to be detectable.
Discussion
The aim of this study was to identify the minimum panel
of membrane markers that may be suitable for detection
of invasive breast cancer by molecular imaging. In order
to determine this combination, we stained TMAs con-
sisting of 483 clinical specimens of invasive breast
Table 2 Frequency of expression by
immunohistochemistry of tumor-specific and less tumor-
specific membrane markers in breast cancers
Target Positive Negative Missing
N % N % N %
HER2 50 10.4 432 89.4 1 0.2
EGFR 84 17.4 395 81.8 4 0.8
MET 43 8.9 423 87.6 17 3.5
IGF1-R 62 12.8 400 82.8 21 4.3
GLUT1 98 20.3 360 74.5 25 5.2
CAIX 46 9.5 414 85.3 25 5.2
TfR 70 14.5 402 83.2 11 2.3
CD44v6 308 63.8 160 33.1 15 3.1
CAXII 42 8.7 426 88.2 15 3.1
Mammaglobin 81 16.8 382 79.1 20 4.1
MUC1 438 90.7 26 5.4 19 3.9
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Figure 2 Detection rate of tumor-specific membrane markers for detection of breast cancer. Detection rate of highly tumor-specific
membrane markers for detecting luminal, HER2-driven, basal/triple negative ductal breast cancers, and lobular breast cancers. The detection rate
of tumor-specific markers for detection of breast cancer plotted as the positivity of the marker in combination with all preceding markers.
Table 3 Expression of a panel of membrane markers in
various histological types of breast cancer
Target Ductal
(319 cases)
Lobular
(126 cases)
Other
(38 cases)
N % N % N %
HER2 43 13.5 4 3.2 3 7.9
EGFR 71 22.3 4 3.2 9 23.7
MET 34 10.7 4 3.2 5 13.2
IGF1-R 48 15.0 7 5.6 7 18.4
GLUT1 85 26.6 5 4.0 8 21.1
CAIX 38 11.9 2 1.6 6 15.8
TfR 53 16.6 10 7.9 7 18.4
CD44v6 197 61.8 82 65.1 29 76.3
CAXII 30 9.4 12 9.5 1 2.6
Mammaglobin 44 13.8 34 27.0 3 7.9
MUC1 218 88.1 119 94.4 38 100
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cancer by immunohistochemistry. Based on the expres-
sion profiles in the normal breast tissue, we defined
highly tumor-specific (no or low staining of the normal
breast tissue) and less tumor-specific (moderate or high
staining of the normal breast tissue) membrane targets.
We found that the expression of highly tumor-specific
targets (HER2, EGFR, GLUT1, CAIX, IGF1-R, and
MET) is quite dependent on the tumor histology and
molecular subtype: ductal cancers and in particular the
basal/TN and HER2-driven subtypes express more fre-
quently highly tumor-specific membrane targets than
lobular cancers.
Because the individual tumor-specific markers are
clearly not sensitive enough, application of a tumor-
specific panel of tracers is required to detect all types of
breast cancer. A panel of tumor-specific markers
(GLUT1, EGFR, HER2, IGF1-R, MET, and CAIX) was in
the present study able to 'detect' 45.5% of all cancers
and 55.6% of ductal cancers. For lobular cancers and
low-grade tumors, the panel was not very suitable be-
cause with detection rates of 18.3% and 22.5%, respect-
ively. Addition of less tumor-specific markers
theoretically increased the detection rate to 98.1% using
MUC1, but of the less tumor specific markers only
CD44v6 met the desired 3-fold tumor-to-normal tissue
ratio measured by image analysis. When adding CD44v6
to the panel, 80.1% of all cancers could be ‘detected’ with
Table 4 Expression of membrane markers in molecular
subtypes of ductal breast cancer
Target Luminal
(242 cases)
HER2-driven
(20 cases)
Basal/TN
(57 cases)
N % N % N %
HER2 23 9.5 20 100 0 0.0
EGFR 25 10.3 11 55 35 61.4
MET 21 8.7 4 20 9 15.8
IGF1-R 41 16.9 2 10 5 8.8
GLUT1 49 20.2 6 30 30 52.6
CAIX 11 4.5 4 20 23 40.4
TfR 33 13.6 5 25 40 70.2
CD44v6 148 61.8 9 45 15 26.3
CAXII 28 11.6 1 5 1 1.8
Mammaglobin 39 16.1 4 20 1 1.8
MUC1 213 88.0 20 100 48 84.2
Figure 3 Quantitation of expression levels of less tumor specific markers using immunofluorescence. Expression levels of less tumor-
specific membrane markers (CD44v6, MUC1, Mammaglobin, and CAXII) as determined by immunofluorescence resulted in staining patterns in
normal breast epithelium and positive tumors comparable to conventional immunohistochemistry (Transferrin Receptor was not detectable). Size
bar equals 25 μm.
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at least one marker in a panel consisting of HER2,
GLUT1, EGFR, IGF1-R, and CD44v6. CAIX and MET
had no additional effect on the sensitivity of the panel
once CD44v6 had been included.
Our estimation of positivity of breast cancers for our
panel may have been conservative since we have been
very stringent in calling expression positive, explaining
why our rates of expression for GLUT1, CAIX, EGFR,
MET, TfR, CAXII, and Mammaglobin are on the lower
side compared to the literature [22,34-43]. Tumors with
1+ membrane staining were consistently considered
negative as we expect that this level of staining provides
insufficient signal-to-noise, but only in vivo studies can
confirm this. Moreover, quantification of expression
levels based on image analysis of immunohistochemical
stainings may be hampered by the non-linear amplifica-
tion of the signal during immunohistochemistry. For
that reason we applied immunofluorescence of directly
labeled antibodies for more reliable quantitation of pro-
tein expression. Tumor-to-normal ratios above 3 where
only obtained when tumors are scored as DAKO 2+ or
3+ membranous staining. This justifies the predefined
thresholds for calling tumors positive. Furthermore,
cytoplasmic staining was ignored as imaging antibodies
will not be easily internalized and will have to bind to
receptors on the outside of the cancer cells. Lastly, using
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Figure 4 Optimal combination of membrane markers for detection of breast cancer correlated with clincopathological characteristics.
A. The contribution of each tumor-specific and less tumor-specific membrane marker in the optimal panel for detection of breast cancer. B. The
detection rate of the panel with respect to several clinicopathological features.
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TMAs may have resulted in slight underestimation of
GLUT1 and CAIX expression, because the expression is
usually limited to hypoxic areas within the tumor
[44,45].
Adding further candidate tumor markers may enable
to improve the results of our panel of membrane related
markers. For instance, biomarkers that are specifically
expressed in the stroma of breast cancers like growth
factors (e.g. VEGF) may be valuable.
This study provides information on the expression
levels of membrane bound targets for imaging using par-
affin embedded material of invasive breast cancers. To
be suitable for breast cancer detection or screening,
multiple steps have to be taken before tracer develop-
ment and testing in (pre)clinical trials results in treat-
ment of patients. However, the present study elucidates
which targets might be most suitable based on the ex-
pression in cancer vs. normal breast tissue. One of the
current challenges is specific detection of lobular breast
cancers and DCIS, because these lesions are difficult to
detect by mammography. DCIS was beyond the scope of
the current paper, but for detection of lobular breast
cancer CD44v6 is potentially quite useful.
Next to expression of target proteins, tumor perfusion
and penetration of the tracer into the tumor could influ-
ence the signal for imaging. Further, affinity after label-
ing and half-life of the tracer in the human body
determine the tumor-to-background ratio and thus the
applicability of a tracer in a clinical setting. Based on
preclinical studies using NIRF labeled trastuzumab and
bevacizumab, the maximal tumor-to-background ratio
was obtained 6 days post injection [33]. Optimizing this
by reducing the half-life of the tracer would be beneficial
for clinical practice.
The present study underlines that no single membrane
marker probe is likely to detect all breast cancers by mo-
lecular imaging, and that a panel of least five probes
may be required. So far, experience is however limited to
maximally two different tracers at once. Barrett et al.
[46] showed that two antibodies allowed to identify dif-
ferences in tumor expression of HER2 and EGFR in vivo.
When aiming to be just discriminative between tumor
and normal, a panel of markers can be injected with the
same probe attached to simplify imaging. Feasibility and
toxicity of injecting a panel of markers require further
in vivo experiments in mouse models.
Conclusions
We studied which tumor membrane markers are most
discriminating between invasive breast cancer and nor-
mal breast tissue in order to identify the minimal num-
ber of targeted probes needed for the highest possible
breast cancer detection rate. We showed that 80% of all
breast cancers express at least one of a panel of markers
(CD44v6, GLUT1, EGFR, HER2, and IGF1-R) that there-
fore may be suitable for molecular imaging strategies.
The present study thereby serves as a starting point for
further development of a set of antibody-based optical
tracers with high potential for detecting breast cancer.
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